Q-omics provides the consensus-scored CDCP2 profile across patient tissues and cancer cell-line models. CDCP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CDCP2 is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, CDCP2 RNA expression shows 12,098 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, UCEC, and TGCT as cancer lineages where CDCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDCP2 survival associations across molecular data types. CDCP2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDCP2 RNA expression–survival associations across cancer types. High CDCP2 expression shows unfavorable associations in KIRP and ESCA, but favorable associations in HNSC, ACC, READ and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for CDCP2 RNA expression.
This table summarizes CDCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDCP2 shows lower tumor expression in UCEC, THCA, KIRP, BRCA and LUSC and higher tumor expression in CHOL. The UCEC box plot shows higher CDCP2 RNA expression in normal versus tumor tissue (log2 FC = −0.103, t-test p = .005).
This table shows molecular features associated with CDCP2 in patient tissues and cancer cell lines. In patient samples, CDCP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CDCP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
